Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Nomura Asset Management Co. Ltd.

Nomura Asset Management Co. Ltd. lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 7.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 85,445 shares of the biopharmaceutical company's stock after acquiring an additional 6,148 shares during the period. Nomura Asset Management Co. Ltd. owned 0.07% of Alnylam Pharmaceuticals worth $23,500,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Huntington National Bank lifted its holdings in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at about $29,000. Ashton Thomas Private Wealth LLC purchased a new stake in Alnylam Pharmaceuticals in the second quarter valued at about $26,000. Washington Trust Advisors Inc. acquired a new stake in Alnylam Pharmaceuticals in the third quarter worth about $42,000. Finally, True Wealth Design LLC grew its stake in shares of Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 153 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock traded up $0.24 during trading hours on Wednesday, hitting $254.15. 453,455 shares of the company's stock were exchanged, compared to its average volume of 862,560. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The firm has a market cap of $32.78 billion, a P/E ratio of -97.00 and a beta of 0.32. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The firm has a 50 day moving average of $267.94 and a two-hundred day moving average of $247.50.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The business's revenue for the quarter was down 33.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.15 EPS. Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a "neutral" rating in a research note on Monday, August 26th. Piper Sandler reiterated an "overweight" rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Bank of America upped their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a "buy" rating in a research report on Monday, October 14th. The Goldman Sachs Group raised Alnylam Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $198.00 to $370.00 in a research report on Friday, August 16th. Finally, Scotiabank increased their price objective on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a "sector outperform" rating in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $298.09.

Insiders Place Their Bets

In other news, EVP Tolga Tanguler sold 1,469 shares of the business's stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. The trade was a 10.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the sale, the chief executive officer now directly owns 78,880 shares of the company's stock, valued at approximately $19,797,302.40. This represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 8,370 shares of company stock worth $2,100,703. Corporate insiders own 1.50% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.